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Abstract
One of the most important targets in Alzheimer disease is Beta site amyloid precursor 
protein cleaving enzyme-1 (BACE-1). It is a membrane associated protein and is one of 
the main enzymes responsible for amyloid β (Aβ) production. Up to now, a considerable 
number of peptidic and non-peptidic inhibitors of BACE-1 have been developed. Recently, 
small molecule BACE-1 inhibitors have attracted the attention of scientists, because peptidic 
inhibitors have many pharmacokinetic problems. In the present study, several small molecule 
BACE-1 inhibitors were extracted from Brookhaven Protein Databank (PDB) and subjected 
to dissection analysis to achieve constructing fragments. Atom type, hybridization, and bond 
order were considered for generated constitutional fragments (simplified structures). AutoDock 
version 4.2 was applied to dock various chemical fragments into BACE-1 active site. The 
benefits of such studies have been well revealed in previous reports. On the basis of obtained 
binding affinities, fragment-based ligand efficiency (LE) indices were estimated. These 
theoretical binding efficiencies were applied to further elucidate the key structural features of 
BACE-1 inhibitors. Typical results of the study were elucidated and we suggested the ways 
these findings might be beneficial to guide rational bioactive molecular developments. Our 
study confirmed that the evaluation of ligand-receptor interactions in terms of ligand efficiency 
indices (binding energy per atom and pKi per MW) could be a helpful strategy in structure-
based drug discovery (SBDD) strategies.
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Introduction
Alzheimer disease was diagnosed for the 
first time in a German patient named Alois 
Alzheimer (1). It is one of the diseases affecting 
a large number of people all over the world; 
being the most common cause of dementia in the 
elderly (1, 2). The amyloid cascade hypothesis 
proposes that aggregation of amyloid beta 40 
and 42 (Aβ40 and Aβ42) oligopeptides followed 
by generation of neurotoxic plaques in brain 
as commonly occurring features in AD (3). 
Proteolytic cleavage of a large trans-membrane 
protein, amyloid precursor protein (APP), by 
two enzymes namely β and γ-secretases results 
in secretion of Aβ40 and Aβ42 peptides (4,5). 
β-secretase (Beta-site APP cleaving enzyme 
or BACE-1) is a type I membrane-associated 
aspartyl protease (3), which has been an 
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In the present work, the PDB database was 
screened for potential small molecule BACE-
1 inhibiting molecules and 83 structures 
were extracted for our structure-based 
study. Dissection analysis was performed on 
two-dimensional structures of the selected 
compounds. This shape-based analysis resulted 
in fragments, graph-based frameworks and side 
chains. Obtained fragments were subjected to 
docking simulations into BACE-1 active site 
and results were further discussed for binding 
energies and binding efficiency indices.
Computational section
Chemical structures of ligands under 
study were all extracted from Holo PDB files 
documented in PDB database (83 PDB codes). 
Our criterion for selected molecules considered 
chemical structures bearing 10 or less rotatable 
bonds after dissection into simplified structures 
(19). Molecular descriptors were calculated by 
Dragon software version 2.1 (20).
Flexible-ligand docking studies were 
performed using AutoDock 4.2 program (21). All 
the pre-processing steps for ligand and receptor 
crystallographic files were performed within 
WHAT IF server (European Molecular Laboratory 
Heidelberg, Germany) and AutoDock Tools 1.5.4 
program (ADT) which has been released as an 
extension suite to the Python Molecular Viewer 
(22, 23). All hydrogens were properly added 
to the receptor PDB file using What if server. 
ADT program was used to merge non-polar 
hydrogens into carbon atoms of the receptor 
and Kollman charges were also assigned. For 
docked ligands, non-polar hydrogens were also 
added. Gasteiger charges assigned and torsions 
degrees of freedom allocated by ADT program. 
Chemical fragments were docked into BACE-
1 active site holding their initial conformation 
unchanged. The Lamarckian Genetic Algorithm 
(LGA) was applied to model the interaction 
pattern between BACE-1 and inhibitors. For all 
docking procedures, 150 independent genetic 
algorithm (GA) runs were considered for each 
molecule under study. A maximum number of 
5×106 energy evaluations; 27000 maximum 
generations; a gene mutation rate of 0.02  and a 
crossover rate of 0.8 were used for Lamarckian 
genetic algorithm. The grid maps representing 
attractive therapeutic target in AD due to the fact 
that it catalyzes the first step in Aβ production 
and is mainly expressed in brain. 
Therefore, development of specific inhibitors 
of these key proteases has been regarded as 
a major therapeutic target in AD treatment 
and many research groups have focused on 
development of beta-secretase inhibitors 
(6, 7). Nowadays, it is generally accepted 
that biologically potent compounds will not 
necessarily end in good drugs and that there are 
several critical parameters along the discovery 
process such as MW or partition coefficient 
responsible for the optimal pharmacological 
outputs (8). These simple property counting rules 
have been applied successfully to distinguish 
between drugs and non-drugs (9-11). 
Experimental measurement of binding 
affinities for huge molecular libraries is a time-
consuming and non-economic process being a 
major bottle-neck in the field of drug discovery. 
To overcome this limitation, virtual screening 
techniques have found their usefulness in finding 
potential bioactive compounds prior to synthesis. 
The concept of interpreting ligand-receptor 
interaction in terms of the free energy per atom 
(ligand efficiency, LE) was first proposed by P. 
Andrews (12). Consequently several efficiency 
indices have been proposed by other groups 
(13). These ligand-based efficiency indices are 
now regarded as undeniable part of modern lead 
development strategies (14, 15). In this regard, 
the use of structure-based calculated binding free 
energies (16) instead of experimental binding 
affinities may become successful alternative 
for obtaining LEs. Estimated LEs may offer 
negligible time and, consequently, reduce 
time-consuming and expensive biochemical 
measurements. In an AutoDock based study, 
BACE-1 inhibitors were used to correlate the 
estimated and experimental LEs. Results showed 
an acceptable correlation among the data (17).
Availability of a significant amount of 
crystallographic data on Protein Data Bank 
(PDB, http://www.rcsb.org) has facilitated the 
performance of structure based drug discovery 
projects aiming at beta-secretase as a molecular 
target for Alzheimer disease. Holo X-ray 
crystallographic structures which bear cognate 
ligands are principal sources for this purpose (18). 
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BACE-1 in the docking process were calculated 
using AutoGrid (part of the AutoDock package) 
with a grid spacing of 0.375 Å (roughly a quarter 
of the length of a carbon–carbon single bond). 
A grid of 60, 60, and 60 points in x, y, and z 
directions was centered on the center of mass 
of the active site of BACE-1 since the locations 
of the original ligands (cognate ligands) in the 
complex were known. Cluster analysis was 
performed on the docked results using a root 
mean square (RMS) tolerance of 2 Å. Schematic 
2D representations of the ligand-receptor binding 
maps were generated using LIGPLOT (24).
Results and Discussion
Dissection analysis of BACE-1 inhibitors
In order to better recognize the structural 
features of BACE1 inhibitors, we used a 
fragmentation method on the compounds 
originated from PDB database. BACE1 inhibitors 
were classified into several constructive units. 
Chemical structures and their fragments are 
depicted in a hierarchy model in Figure 1. The 
advantages of such dissection methods have 
been well established in previous reports (25). 
Frameworks are molecular descriptions 
on the basis of graph theory in which atoms 
and bonds are depicted as vertexes and 
edges of a graph ignoring atom types, atomic 
hybridizations, atomic charges and bond orders 
(26). In scaffolds, molecular properties such as 
atom type, atom hybridization and bond order 
are incorporated. Side chains are non-ring, 
non-linker atoms. Linker atoms are situated 
at the pathway connecting ring systems. One 
distinguished feature in our present study is that 
we considered linkers without any elimination 
of functional groups such as carbonyl moieties 
or other side branches. In this way, detailed 
structural features of linker groups maybe 
provided. PDB codes of BACE-1 inhibitors and 
related fragments are summarized in Table 1. 
It was crucial to retain the atomic 
hybridizations within simplified structures 
when side chains were removed, therefore, dot 
pairs were considered next to the sp2 atoms to 
designate the related π electrons (25). No acyclic 
molecule was found and all structures under 
study possessed at least one ring system. The 
thing which is worth noting is the definition 
of ring and cycle. The cycles alone or fused to 
other cycles represent a unit ring system within 
each molecule. Graph-based frameworks and 
simplified structures of small molecule BACE1 
inhibitors are shown in Figures 2 and 3. 
As it would be expected, classification scheme 
based on frameworks represented less diversity 
compared to the molecular scaffolds, because 
atom types, hybridizations and bond orders 
were not incorporated. Most of the evaluated 
BACE-1 inhibitors could be represented with 13 
independent frameworks (Figure 2). 
Ligand efficiency indices
Ligand efficiency index can be simply 





HAC stands for heavy atom count. Concept 
Figure 1. Hierarchical dissection of BACE-1 inhibitors.
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PDB code
HACa HDsb HAsc MW
ligand / fragment ligand / fragment ligand / fragment ligand / fragment
1TQF 40 / 28 4 / 1 9 / 6 571.7 / 395.1
1W51 39 / 28 3 / 3 7 / 4 531.7 / 374.2
2EWY 38 / 37 3 / 3 5 / 5 504.6 / 490.2
2F3F 34 / 19 5 / 3 8 / 3 514.7 / 297.1
2IQG 41 / 28 3 / 3 6 / 6 677.6 / 374.2
2OF0 19 / 17 1 / 1 4 / 4 265.3 / 237.1
2OHL 13 / 10 2 / 0 2 / 1 144.2 / 129.1
2OHK 13 / 10 2 / 0 2 / 1 144.2 / 129.1
2OHM 15 / 14 3 / 1 3 / 2 199.3 / 184.1
2OHN 15 / 13 1 / 1 1 / 1 193.3 / 175.1
2OHP 21 / 17 3 / 1 3 / 2 237.3 / 222.1
2OHQ 23 / 20 2 / 0 3 / 1 304.4 / 259.1
2OHR 23 / 20 3 / 1 4 / 3 276.3 / 261.1
2OHS 24 / 20 3 / 1 5 / 3 306.4 / 261.1
2OHT 24 / 23 4 / 2 4 / 3 314.4 / 299.1
2OHU 32 / 31 4 / 2 6 / 5 421.5 / 406.2
2P83 44 / 28 5 / 3 10 / 4 610.7 / 374.2
2Q11 31 / 30 2 / 0 6/ 5 288.4 / 403.2
2Q15 37 / 36 2 / 0 6 / 5 496.6 / 487.3
2QK5 42 / 28 3 / 3 7 / 4 581.7 / 374.2
2QMD 44 / 32 3 / 3 7 / 5 607.7 / 430.2
2QMF 43 / 31 3 / 3 7 / 5 593.7 / 416.2
2QP8 40 / 25 3 / 3 7 / 4 559.7 / 338.2
2QU2 24 / 17 4 / 1 5 / 1 318.4 / 219.1
2QU3 29 / 17 4 / 0 5 / 0 427.9 / 236.1
2VA5 19 / 17 4 / 2 5 / 3 254.3 / 223.1 
2VA6 24 / 18 2 / 1 5 / 2 323.4 / 234.1
2VA7 26 / 18 2 / 1 5 / 2 341.4 / 234.1
2WF4 40 / 35 2 / 4 9 / 7 554.7 / 492.2
2WJO 35 / 34 3 / 1 4 / 5 473.6 / 458.2
2ZDZ 35 / 24 4 / 1 7 / 2 486.9 / 311.1
2ZE1 34 / 26 5 / 2 7 / 3 516.4 / 338.1
2ZJH 20 / 13 1 / 0 3 / 1 292.4 / 175.1
2ZJI 24 / 13 1 / 0 5 / 1 352.5 / 175.1
2ZJJ 20 / 13 2 / 1 4 / 2 297.4  / 176.1
2ZJK 21 / 13 2 / 1 4 / 2 311.4  / 176.1
2ZJL 15 / 13 1 / 0 5 / 1 431.4  / 175.1
2ZJM 35 / 24 3 / 1 9 / 4 526.1 / 324.1
2ZJN 36 / 24 3 / 1 9 / 4 540.1 / 324.1
3BRA 10 / 6 3 / 0 2 / 0 137.2 / 78.1
3BUF 11 / 6 3 / 0 2 / 0 151.2 / 78.1
Table 1. Calculated descriptors for BACE-1 inhibitors (PDB codes) and their fragments.
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3BUG 12 / 6 3 / 0 2 / 0 165.2 / 78.1
3BUH 16 / 12 3 / 0 2 / 0 219.3 / 160.1
3CIB 44 / 32 3 / 3 6 / 4 605.8 / 428.2
3CIC 45 / 32 3 / 3 8 / 5 620.7 / 427.2
3CID 44 / 31 3 / 3 8 / 5 606.7 / 413.2
3DV5 35 / 27 3 / 4 6 / 4 487.7 / 372.2
3EXO 25 / 19 2 / 1 6 / 3 340.4 / 247.1
3FKT 36 / 30 2 / 1 7 / 4 491.6 / 400.2
3H0B 28 / 19 3 / 1 8 / 2 386.4 / 248.1  
3HVG 11 / 6 3 / 1 4 / 2 153.2 / 80.1
3HW1 16 / 15 2 / 0 4 / 3 214.3 / 199.1
3IGB 22 / 19 2 / 0 4 / 3 418.5 / 275.1
3IN3 26 / 23 2 / 1 6 / 4 343.4 / 298.1
3IN4 30 / 23 2 / 1 7 / 5 400.5 / 299.1
3IND 24 / 21 2 / 1 4 / 2 323.5 / 278.2
3INE 27 / 21 2 / 1 5 / 2 367.5 / 278.2
3INF 29 / 23 2 / 1 6 / 3 386.4 / 297.1
3INH 32 / 23 2 / 1 7 / 4 445.4 / 298.1
3IVH 34 / 28 3 / 3 4 / 4 472.6 / 380.2
3IVI 37 / 31 4 / 4 6 / 6 510.6 / 418.2
3KMX 17 / 6 3 / 0 3 / 0 272.8 / 78.1
3KMY 16 / 14 2 / 0 2 / 1 232.7 / 183.1
3KN0 24 / 23 2 / 0 4 / 3 321.4 / 306.2
3L3A 32 / 24 2 / 0 5 / 2 442.9 / 310.2
3L5B 20 / 12 2 / 1 4 / 2 293.8 / 158.1
3L5C 32 / 23 4 / 3 8 / 5 432.3 / 306.1
3L5D 28 / 12 4 / 1 7 / 2 387.5 / 158.1
3L5E 39 / 33 3 / 2 7 / 4 535.8 / 446.3
3L5F 23 / 20 2 / 2 4 / 2 319.5 / 274.2
3L38 33 / 31 2 / 0 6 / 5 453.9 / 404.1
3L58 42 / 28 3 / 3 7 / 4 581.7 / 374.2
3L59 17 / 12 2 / 1 4 / 2 251.7 / 158.1
3LHG 28 / 23 2 / 1 5 / 3 378.4 / 297.1
3LNK 45 / 33 3 / 3 7 / 6 620.7 / 443.2
3LPI 46 / 34 3 / 3 7 / 7 656.8 / 479.2
3LPJ 44 / 32 3 / 3 7 / 6 606.7 / 429.2
3MSJ 15 / 9 3 / 1 4 / 2 225.7 / 118.1
3MSK 24 / 22 2 / 0 5 / 4 348.9 / 299.2
3MSL 25 / 23 3 / 1 5 / 4 347.9 / 313.2
3MSM 28 / 26 3 / 1 5 / 4 400.9 / 351.2
3PI5 29 / 24 3 / 1 5 / 1 480.4 / 337.2
3QBH 38 / 27 3 / 2 8 / 3 544.7 / 380.2
aHAC: Heavy atom count (number of atoms other than hydrogen). bHDs: Hydrogen donors (Ns+Os).cHAs: Hydrogen acceptors 
(NHs+OHs).
Table 1. (Continued)
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of the binding energy per atom or binding 
‘efficiency’ of a ligand could be a useful 
parameter in considering the real potency of 
a compound and hence optimizing fragments 
(27). Molecules that exhibit a distinct potency 
with fewer heavy atoms are by definition more 
efficient (28). Accordingly, obtained simplified 
chemical structures were re-ranked depending 
on their ligand efficiency values to be evaluated 
more sensibly. Regarding the ligand efficiencies, 
C.A. Zapatero et al. postulated that molecular 
weights are prior to the number of non-hydrogen 
atoms in considering the contribution of 
heteroatoms from different rows of the periodic 
table (13). These authors suggested a modified 
efficiency value entitled “binding efficiency 
index” (BEI). This index could be easily 
estimated from Equation 2:
 
)(KDaMW
pKBEI i=  
(Equation 2)
The importance of BEI can be emphasized 
as an increase in molecular weight at the 
clinical candidate step, which is regarded as 
an undeniable paradox with a common trend 
towards lower MWs and better pharmacokinetic 
profiles in marketable drugs (29). 
Molecular fragments were subjected to 
validated docking study into BACE1 active site. 
Auto Dock scores were used to rank docked 
fragments. Experimental biological data (In-
vitro FRET Assay) were correlated well with our 
estimated free binding energies (30). Calculated 
free binding energies, LE and BEI values for our 
studied fragment are introduced in Table 2.
Docked energies (BEs) and related efficiency 
indices were normalized and plotted (Figure 4). 
The distribution of LE and BEI patterns were 
relatively the same while estimated binding 
energies followed a different pattern (Figure 4). 
According to the plots, some useful hints may be 
concluded.
- The analogous distribution pattern of LE 
and BEI efficiency plots may be attributed to the 
proximity of varying scaffold heteroatoms (N, O 
and carbon) in a periodic table. 
- As would be expected, the biggest 
difference between LEs and BEIs occurred in the 
case of BACE-1 inhibiting fragments bearing 
two sulfur atoms (2F3F, No.4 in Figure 4). 
Different BEI and LE values could be predicted 
in scaffolds possessing heavier heteroatoms such 
as sulfur or phosphorous in ring(s) or spacer(s). 
Estimated binding energies could not be 
often used to define priorities among bioactive 
compounds while meaningful priorities may 
be established regarding LEs or BEIs. An 
appropriate example can be observed in the 
case of isophthalamide (3CIB, No.44 in Figure 
4) and phenoxepine (2EWY, No.3 in Figure 4) 
derived fragments. In our docking study, these 
molecules exhibited identical binding energies 
to the BACE-1 active site, however, higher BEI 
and LE scores were assigned to isophthalamides. 
Crystallographic ligands identified by 2VA6, 
2QU3 and 2VA7 codes in PDB database are 
Figure 2. Abundant Graph-based frameworks of evaluated BACE-1 inhibitors documented in the Brookhaven protein databank as a 
result of dissection analysis.




































































































1 1TQF -10.14 7.43 0.362 18.81 43 3BUH -5.19 3.80 0.433 23.75
2 1W51 -10.55 7.73 0.377 20.67 44 3CIB -12.96 9.50 0.405 22.19
3 2EWY -12.96 9.50 0.350 19.39 45 3CIC -12.79 9.37 0.399 21.94
4 2F3F -9.83 7.21 0.517 22.18 46 3CID -12.46 9.13 0.403 22.11
5 2IQG -11.02 8.08 0.394 20.10 47 3DV5 -11.67 8.55 0.432 23.04
6 2OF0 -5.66 4.15 0.333 17.51 48 3EXO -6.56 4.81 0.345 19.47
7 2OHL -4.80 3.51 0.480 27.21 49 3FKT -8.98 6.58 0.310 16.45
8 2OHK -4.27 3.13 0.427 24.26 50 3H0B -6.47 4.74 0.341 19.11
9 2OHM -4.53 3.32 0.324 18.04 51 3HVG -2.63 1.93 0.438 24.12
10 2OHN -4.09 3.01 0.315 17.20 52 3HW1 -5.37 3.94 0.358 19.80
11 2OHP -5.32 3.91 0.313 17.61 53 3IGB -6.57 4.82 0.313 17.53
12 2OHQ -6.77 4.96 0.339 18.04 54 3IN3 -7.47 5.48 0.325 18.39
13 2OHR -5.75 4.22 0.288 16.17 55 3IN4 -6.25 4.58 0.271 15.32
14 2OHS -5.68 4.18 0.288 16.01 56 3IND -6.72 4.93 0.320 16.88
15 2OHT -5.76 4.22 0.240 14.11 57 3INE -6.65 4.88 0.317 16.71
16 2OHU -8.23 6.03 0.265 14.85 58 3INF -7.00 5.13 0.304 17.27
17 2P83 -10.96 8.03 0.391 21.47 59 3INH -6.93 5.08 0.301 17.05
18 2Q11 -9.16 6.72 0.306 16.67 60 3IVH -10.79 7.91 0.385 20.82
19 2Q15 -10.22 7.49 0.292 15.84 61 3IVI -11.39 8.35 0.367 19.98
20 2QK5 -10.86 7.96 0.388 21.28 62 3KMX -3.27 2.40 0.545 30.77
21 2QMD -12.75 9.35 0.398 21.74 63 3KMY -4.06 2.99 0.290 16.34
22 2QMF -12.44 9.12 0.401 21.92 64 3KN0 -5.98 4.40 0.260 14.38
23 2QP8 -11.11 8.15 0.444 24.11 65 3L3A -6.12 4.50 0.255 14.52
24 2QU2 -5.95 4.36 0.350 19.91 66 3L5B -4.36 3.19 0.363 20.10
25 2QU3 -5.55 4.08 0.326 17.29 67 3L5C -7.35 5.39 0.320 17.61
26 2VA5 -5.89 4.33 0.347 19.42 68 3L5D -4.15 3.04 0.355 19.24
27 2VA6 -6.13 4.49 0.341 19.19 69 3L5E -9.78 7.17 0.296 16.08
28 2VA7 -6.65 4.87 0.333 18.59 70 3L5F -7.44 5.45 0.372 20.19
29 2WF4 -13.19 9.67 0.388 19.65 71 3L38 -8.57 6.27 0.276 14.93
30 2WJO -9.84 7.21 0.315 15.74 72 3L58 -11.84 8.68 0.377 23.20
31 2ZDZ -8.07 5.91 0.336 19.00 73 3L59 -4.26 3.12 0.355 19.75
32 2ZE1 -8.47 6.21 0.326 18.37 74 3LHG -7.29 5.34 0.317 17.98
33 2ZJH -5.62 4.12 0.432 23.54 75 3LNK -11.24 8.27 0.363 18.67
34 2ZJI -5.47 4.01 0.421 22.91 76 3LPI -13.82 10.13 0.406 21.14
35 2ZJJ -7.78 5.71 0.598 32.44 77 3LPJ -14.16 10.38 0.397 24.19
36 2ZJK -7.21 5.29 0.555 30.06 78 3MSJ -4.37 3.20 0.486 27.12
37 2ZJL -5.85 4.29 0.423 24.51 79 3MSK -6.71 4.92 0.305 16.45
38 2ZJM -9.29 6.81 0.387 21.02 80 3MSL -6.45 4.73 0.280 15.11
39 2ZJN -9.21 6.78 0.384 20.93 81 3MSM -7.67 5.62 0.295 16.01
40 3BRA -3.31 2.43 0.552 31.15 82 3PI5 -10.76 7.88 0.448 23.38
41 3BUF -3.19 2.34 0.532 30.00 83 3QBH -10.98 8.05 0.407 21.18
42 3BUG -2.99 2.20 0.498 28.21
Table 2. Docked binding energies, ligand efficiencies (LEs) and binding energy indices (BEIs) of fragments derived from crystallographic 
BACE-1 inhibitors.
aAll the docking protocols were done on validated holo structures with RMSD values below 2 Å. bThe Reference value for SE is 0.29 (27). 
cThe Reference value for BEI is 27.0 (13).
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Figure 3. Fragments of BACE-1 inhibitors documented in the 
Brookhaven protein databank as a result of dissection analysis 
(Each structure is designated by attributed PDB code(s) and LE 
values in kcal.mol-1 unit).
potent BACE-1 inhibitors in micromolar range 
(http://www.pdb.org). These molecules are based 
on the diphenylthiophene (2QU3, Figure 5) and 
biphenyl dihydropyrimidinone (2VA6 & 2VA7, 
Figure 5) scaffolds exhibiting relatively low 
interaction energies in our docking evaluation 
while showing better BEI and LE indices (Table 
3, Figure 4). As another example, benzimidazole 
fragment (3MSJ, No.78 in Figure 4) was found 
to be a weak BACE-1 inhibitor considering its 
docked binding energy. However, focus on the 
BEI value (and to the less extent LE value) 
demonstrated the efficiency of this scaffold for 
possible lead development strategies. 
In some cases, high-ranked binding energies, 
LEs and BEIs were obtained. Chemical fragments 
possessing this feature provide optimum cases 
in developing potent BACE1 inhibitors. Some 
related examples included 3PI5, 3L5C, 3KN0, 
2OHT, 3L3A, 2ZE1, 2ZDZ, 2QP8, 3IN4, 2ZJN 
and 3MSL based fragments. Our results revealed 
that benzylpiperazines (2ZJJ and 2ZJK) had 
higher docked energies among evaluated 
compounds. 3LPJ derived fragment exhibited 
highest estimated docked energy and also good 
efficiency indices. 3LPJ derived fragment 
may be an efficient scaffold to develop potent 
BACE-1 inhibitors (Table 2). This particular 
case can also be assessed from another aspect. 
Based on docking outputs, isophthalamides 
and benzylpiperazines have been found to be 
efficient BACE-1 inhibitors and one of the most 
potent compounds in PDB database (3LPJ) is 
a chimeric (hybrid) molecule comprising of 
these two building blocks. Considering efficient 
building blocks, similar trends may be extended 
for further hybrid potent BACE-1 inhibiting 
structures. 
The case of 4-amino-benzylpiperidines 
is noticeable. Chemical structures bearing 
mercaptobutanamide side chain exhibit higher 
efficiencies and lower docked energies (2ZJH, 
2ZJI and 2ZJL, Figure 6) while 4-amino-
benzylpiperidines comprising phenoxyacetamide 
side chain (2ZJN, 2ZJM, Figure 6) were found 
to be more potent BACE-1 inhibitors (retaining 
acceptable BEI and LE values, Table 3). 
Isosterism and ligand efficiency values
2,5-diphenylpyrrole based fragment (2QU2) 
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 Figure 4. Normalized docking binding energies (dash blue line), ligand efficiencies (solid narrow red line), binding efficiency indices 
(dotted green line) and ΔEs (BEI-LE) (Solid thick violet line) for docked  BACE-1 inhibiting fragments (molecule numbers are attributed 
to the order in Table 2).
Figure 5. BACE-1 inhibitors including diphenylthiophene (2QU3) and biphenyl dihydropyrimidinone (2VA6 & 2VA7) scaffolds.
proved to be a little more potent and efficient 
than 2,4-diphenylthiophene (2QU3) (Table 3). 
Similar situations were observed for the other 
isosteric molecules (3INH and 3LHG; 3IN3 and 
3IN4). Some isosteric substitutions provided 
potential hydrogen donor/acceptor sites for 
binding to the receptor (2OHM and 3KMY, 
3LPJ and 3CIB, Figure 7). Due to the proximity 
of carbon and nitrogen atoms in a periodic table 
(one unit of mass difference) higher efficiency 
values would be expected for these fragments. In 
some cases, these isosteric replacements cause 
significant enhancements in potency results 
(2ZJK and 2ZJL).
Constitutional isomeric structures
The case of constitutional isomeric fragments 
is also worth mentioning. As a typical example 
in our study, we refer to quinoline derivatives. 
Quinoline (2OHL) exhibited superior potency 
and more efficiency than its isomer; isoquinoline 
(2OHK) in binding to BACE-1 active site. 
Our results confirmed that structural isomers 
may have a determinant effect on both binding 
energies and efficiencies. In this particular case, 
both of the isomers show similar enhancement 
patterns in their potency and efficiency profiles. 
For further information, some constitutional 
isomers and their normalized docking-based 
energies and efficiencies are depicted in Table 3.
Side chains in designing potent BACE-1 
inhibitors
For further evaluation of the side chain effect 
on ligand potency, we focused on identical 
isophthalamide simplified structures derived 
from different BACE-1 inhibitors (31-33). 
Experimental BACE-1 inhibitory activities for a 
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Figure 6. Benzylpiperidine-based BACE-1 inhibitors including mercaptobutanamide (2ZJH, 2ZJI and 2ZJL) and phenoxyacetamide 
(2ZJN, 2ZJM) side chains.
Figure 7. 2D schematic interactions of 2OHM a: and 3KMY b: derived fragments with BACE-1 active site generated by LIGPLOT.

























Table 3. Estimated binding/efficiency scores of the isomeric fragments (BACE-1 inhibitors).










1W51 500 -10.55 0.377 20.67
2P83 11 -10.96 0.391 21.47
3L58 15-80 -11.84 0.377 23.20
Priority order 2P83>3L58>1W51 3L58>2P83>1W51 2P83>1W51≈3L58 3L58>2P83>1W51
Table 4. Experimental IC50s for crystallographic BACE-1 inhibitors and structure-based binding indices in related fragments.
number of crystallographic ligands and binding 
characteristics of their docked fragments are 
summarized in Table 4. 
Experimental data showed that the priority 
order was not retained in docked fragments due 
to the absence of side chains. Studied fragments 
possessed 4 heteroatoms in their structures (2 
nitrogen atoms and 2 oxygen atoms) and this 
may also to some extent explain the dissimilar 
observed priority orders for LE and BEI values. 
BE and BEI indices are in good agreement 
with each other. Based on the results, the well-
orientated 3L58 derived fragment is possibly 
an efficient starting point to develop BACE-
1 inhibitors. Different biological activities of 
cognate structures could be attributed to the 
absence or presence of side chains in the meta 
position of isophthalamide ring (Figure 8). It 
should be added that all the evaluated structures 
possessed the same stereochemistry. 
These typical cases may be beneficial in 
quantification studies of side chain effects on 
binding potency of biologically active molecules. 
Conclusion
Docking simulation was applied in 
comparative study of BACE-1 inhibitors. We 
used a simple shape-based dissection method 
to analyze compounds obtained from PDB 
source. This classification route was followed 
by a fragment-based docking strategy to rank 
the structural features of BACE-1 inhibitors. 
The merit of such structure-based efficiency 
indices for various biological targets has been 
well revealed in other studies. Our case study 
confirmed that larger BACE-1 inhibitors may 
require special attention in their design toward 
efficiency indices. According to this, considering 
molecular weights rather than number of heavy 
atoms would produce less biased results. This 
technique leads to more realistic view at the 
individual atom participations in binding to 
the receptor. Comparative studies revealed that 
N-(4-(benzylamino)-3-hydroxy-1-phenylbutan-
2-yl) benzamide could be an appropriate 
fragment for further bioactive molecular 
Figure 8. Chemical structures of isophthalamide-based BACE-1 inhibitors with their relevant PDB codes used for the assessment of 
side chain effects. 
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modifications. Other efficient fragments were 
arylpiperazine, imidazolidinone, pyrimidinone 
and benzoimidazole. Our study confirmed that 
the evaluation of the ligand-receptor interactions 
on the basis of ligand efficiency indices (binding 
energy per atom and pKi per MW) rather than 
free energy of binding (ΔG) could be a helpful 
strategy in recognizing potential candidates for 
further bioactive molecular developments.
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